MANATEE-T1D: Metformin ANd AutomaTEd insulin delivery system Effects on renal vascular resistance, insulin sensitivity, and cardiometabolic function in youth with Type 1 Diabetes
Primary Objective
The purpose of this study is to learn about the health effects of combining two treatments, the automated insulin delivery system and metformin, for people with type 1 diabetes
Details
Age
Child to Adult
Eligibility
Youth ages 12-21 with diagnosis of Type 1 Diabetes on an hybrid closed loop artificial pancreas system OR on multiple daily injections + continuous glucose monitor for at least 6 monthsT1D by ADA criteria
On an HCL AP system OR MDI+CGM for > 6 months
Age 12-21 years
HbA1c < 11%
No recent diabetic ketoacidosis or hyperosmolar hyperglycemia
Tanner stage 2 or greater
Weight > 54 kg and BMI > 5th percentile
Not pregnant or breastfeeding
No use of anti-diabetic agents except insulin, ACE inhibitors, angiotensin receptor blockers (ARB’s), diuretics, daily NSAIDs or aspirin, sulfonamides, procaine, thiazolesulfone or probenecid
No seafood or iodine allergy
Locations
Barbara Davis Center
Childrens Hospital Colorado
Principal Investigator
Kristen Nadeau
Study ID
Protocol Number: 21-3483
More information available at ClinicalTrials.gov: NCT05065372
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers